Cargando…
The 5-HT(2C) receptor agonist, lorcaserin, and the 5-HT(6) receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour
RATIONALE: Whilst the FDA-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-HT)(6) receptor antagonists reduce feeding, a direct assessment of their impact upon feeding behaviour is less clear. We therefore examined the action of lorcaserin and the clinical-stage developmental candid...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710672/ https://www.ncbi.nlm.nih.gov/pubmed/26507195 http://dx.doi.org/10.1007/s00213-015-4112-x |
Sumario: | RATIONALE: Whilst the FDA-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-HT)(6) receptor antagonists reduce feeding, a direct assessment of their impact upon feeding behaviour is less clear. We therefore examined the action of lorcaserin and the clinical-stage developmental candidate 5-HT(6) receptor antagonist, SB-742457, upon microstructural analysis of licking behaviour. Such analysis provides a rich source of information about the mechanisms controlling food intake. OBJECTIVES: The objective of the present study was to gain insight into the influence upon feeding behaviour of the 5-HT(2C) receptor agonist, lorcaserin and the developmental 5-HT(6) receptor antagonist, SB-742457. METHODS: The impact of lorcaserin and SB-742457 upon licking behaviour of non-deprived rats for a glucose solution was assessed using microstructural analysis. RESULTS: Lorcaserin (0.1–3.0 mg/kg) displayed a dose-dependent ability to reduce glucose consumption via reduction in the number of bouts of licking. A similar action was evident with SB-742457, but only at the lowest dose tested (3.0 mg/kg). CONCLUSIONS: The behavioural actions of both lorcaserin and SB-742457 demonstrate they directly promote satiety. |
---|